Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + Gemcitabine + Carboplatin in Metastatic TNBC
NCT00894504Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2010
- Primary completion
- Sep 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in triple negative breast cancer (TNBC), sponsored by SCRI Development Innovations. Started Feb 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00894504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00894504.